Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17
M Takaishi, M Ishizaki, K Suzuki, T Isobe… - Journal of …, 2017 - Elsevier
Background Targeting the IL-17 pathway represents a highly effective strategy for the
treatment of psoriasis, using antibodies against IL-17A and IL-17 receptor, suggesting that
Th17 cells essentially contribute to development of psoriasis. Th17 differentiation depends
on the key transcription factor, RORγt. Objective To develop a novel RORγt antagonist which
is effective on psoriasis via oral administration. Methods A chemical library was screened
using cell-based high-throughput methods, luciferase reporter assay, competitive binding …
treatment of psoriasis, using antibodies against IL-17A and IL-17 receptor, suggesting that
Th17 cells essentially contribute to development of psoriasis. Th17 differentiation depends
on the key transcription factor, RORγt. Objective To develop a novel RORγt antagonist which
is effective on psoriasis via oral administration. Methods A chemical library was screened
using cell-based high-throughput methods, luciferase reporter assay, competitive binding …